Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show
Rhea-AI Summary
Marijuana Inc (OTCPINK:MAJI), operating as Exousia Pro, has received an order to deliver 500 billion dried exosomes for a trade show demonstration. The exosomes will be divided into 100 samples of 5 billion each and mixed into a cream to showcase a new product line.
The company is working with a partner serving over 300 clients (MedSpas and Dermatologist offices) who plans to transition from mammalian to plant-based exosomes in their products. The partner currently sells 1,500 bottles of hair serum monthly and aims to expand their product line using Exousia's mushroom exosomes.
Each 5 billion exosome order sells for $5.00 with a $2.00 manufacturing cost, resulting in a 60% profit margin. Exousia Pro claims to be the only company capable of producing dried plant-based exosomes, offering extended shelf life for medical and cosmeceutical applications.
Positive
- 60% profit margin on exosome sales ($5 revenue vs $2 cost per 5 billion units)
- First-to-market position in plant-based exosomes for topical treatments
- Secured partnership with distributor serving 300+ medical clients
- Unique capability to produce dried plant-based exosomes with extended shelf life
Negative
- Revenue from core cancer treatment development still pending
- Early stage market entry with unproven commercial success
News Market Reaction
On the day this news was published, MAJI declined 20.00%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Exousia Pro has a
ORLANDO, FLORIDA / ACCESS Newswire / April 8, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to announce that it has received an order to deliver 500 billion dried exosomes.
The order of 500 billion exosomes will be mixed into a cream and packaged into 100 samples containing 5 Billion Exosomes each. This will allow the marketing team to showcase a new product using exosomes. They will further demonstrate that exosomes do not alter the feel or consistency of their existing product, which is currently sold at large box stores nationwide. The marketing team will write orders at and after the show, and we anticipate larger orders to follow.
Exousia Pro is working with a company that services over 300 clients, including MedSpas and Dermatologist offices. They currently use mammalian exosomes but want to switch to plant-based to expand their sales channels for those who will not use mammalian for religious or ethical reasons. They sell 1,500 bottles of hair serum per month and plan to switch to plant-based exosomes, expanding their monthly sales volume and product line to feature new products using our mushroom exosomes.
An order of 5 billion exosomes would currently sell for
This order will showcase a significant feature Exousia Pro can offer: the ability to supply dried exosomes. By drying the exosomes, we can increase their shelf life. We believe Exousia Pro is the only Company currently able to produce and supply dried plant-based exosomes, which have many applications in the medical and cosmeceuticals markets.
Matt Dwyer, our President, stated, "Exousia Pro's primary focus is using its exosomes to create new treatments for the world's deadliest cancers. While this process is enriching, it can take time to achieve. During this time, we can use other sales channels to bring in revenue that will allow us to keep our focus on developing these new cancer treatments. We have several new sales channels we will be revealing soon. Using the feedback we receive from these early orders, along with testimonials and pictures, will make our entry into other markets much easier. Currently, no plant-based exosomes are being used in topical treatments, so we are first to market."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
What is the profit margin for Exousia Pro's (MAJI) exosome products?
How many dried exosomes will MAJI deliver for the trade show demonstration?
What is the current monthly sales volume of MAJI's distribution partner?
What competitive advantage does Exousia Pro (MAJI) have in the exosome market?
How many clients does MAJI's new distribution partner serve?
